Showing 7471-7480 of 9550 results for "".
- Michelson Diagnostics Launches Enhanced Software for VivoSight OCT Scannerhttps://practicaldermatology.com/news/20140219-michelson_diagnostics_launches_enhanced_software_for_vivosight_oct_scanner/2459339/Michelson Diagnostics recently launched its upgraded VivoSight Optical Coherence Tomography (OCT) scanner with a new software technology that provides additional f
- ASDS Survey Finds Skin Cancer, Cosmetic Procedures Jump 22 Percent in 2013https://practicaldermatology.com/news/20140213-asds_survey_finds_skin_cancer_cosmetic_procedures_jump_22_percent_in_2013/2459342/Dermatologic surgeons performed nearly 22 percent more medically necessary and cosmetic procedures in 2013 than the previous year, according to statistics released by the American Society for Dermatologic Surgery (ASDS). The survey was conducted January 2 thro
- Revance Therapeutics Announces Pricing of Initial Public Offeringhttps://practicaldermatology.com/news/20140207-revance_therapeutics_announces_pricing_of_initial_public_offering/2459346/Revance Therapeutics, Inc., a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced the pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $16.00 per share, befo
- Valeant Pharmaceuticals Announces FDA Approval of Retin-A Micro Microsphere 0.08%https://practicaldermatology.com/news/20140131-valeant_pharmaceuticals_announces_fda_approval_of_retin-a_micro_microsphere_008/2459353/The FDA approved Valeant Pharmaceuticals' Supplemental New Drug Application (sNDA) for Retin-A Micro (tretinoin) Gel microsphere 0.08% for the topical treatment of acne vulgaris. "We are very pleased that the FDA ha
- AAD Responds to New York Timeshttps://practicaldermatology.com/news/20140127-aad_sumbits_letter_to_the_editor_to_new_york_times/2459358/In response to The New York Times article “Patients' Costs Skyrocket; Specialists' Incomes Soar” (“Paying Till It Hurts” series, Jan. 19, 2014), the American Academy of De
- Anti-Aging Technology Using the “Science of Heat” to be Presented at AACShttps://practicaldermatology.com/news/20140117-anti-aging_technology_using_the_science_of_heat_to_be_presented_at_aacs/2459368/An anti-aging technology that uses the “science of heat” will be presented tomorrow at the American Academy of Cosmetic Surgery (AACS) 30th Annual Scientific Meeting in Fort Lauderdale, FL. ThermiRF is a minimally invasive method of tightening sagging skin and reducing the appearance of fine lines a
- Injectable Methotrexate Product Now Availablehttps://practicaldermatology.com/news/20140117-injectable_methotrexate_product_now_available/2459369/For patients who do not tolerate oral methotrexate for psoriasis, a new recently approved injectable methotrexate product is now available from Antares Pharma. Approved in October 2013 for the subcutaneous methotrexate product for once weekly self-administration, Otrexup is indicated for use in adul
- FDA Approves Combination Use of GSK's Mekinist® (trametinib) and Tafinlar® (dabrafenib)https://practicaldermatology.com/news/20140109-fda_approves_combination_use_of_gsks_mekinist_trametinib_and_tafinlar_dabrafenib/2459375/GlaxoSmithKline plc [LSE/NYSE: GSK] has received FDA approval of Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma or metastatic melanoma with BRAF V600E or V600K mutation
- First Practice in Northwest Adopts ARTAS® Robotic Systemhttps://practicaldermatology.com/news/20131230-first_practice_is_northwest_adopts_artas_robotic_system/2459386/Advanced Hair Restoration of Bellevue, WA has installed the revolutionary ARTAS® Robotic System — the first and only FDA-cleared, physician-controlled, computer-assisted techno
- Syneron's Home-Use Hair Removal Systems Receive Expanded Indicationhttps://practicaldermatology.com/news/20131219-synerons_home-use_hair_removal_systems_receive_expanded_indication/2459390/The FDA has granted Syneron Medical Ltd. and Iluminage Beauty an expanded indication for me™ brand of home-use hair removal systems. The systems, which utilize Syneron's proprietary elos technology, are now indicated for permanent reduction in hair growth. The me™ brand is owned and sold by Iluminag